The dynamic intersection of regulatory policy and pharmaceutical innovation has once again taken centre stage as the US undergoes administration changes, while simultaneously working through the evolution and effects of the Inflation Reduction Act (IRA) and the Recovering Excessive Funds for Unused and Needless Drugs (REFUND) Act. Understanding the implications of these Acts for pharmaceutical manufacturers (Figure 1), both in the US and abroad, demands rigorous examination, while embracing a level of uncertainty in light of the presidential administration transition.
This evolving landscape underscores the potential for drug delivery partnerships to successfully address the complexities of modern healthcare trends. Eitan Medical’s expertise in infusion technology, together with its commercial product experience, global presence, flexibility in pharmaceutical partnerships and robust portfolio of connected, infusion solutions – including the Sapphire™ and Avoset™ infusion pump platforms and the Eitan Insights™ digital health platform – position it as a pivotal partner of the pharmaceutical industry as it navigates these challenges.
